Loading…
Employees: 1,850
Size Embecta (EMBC) is a United States Health Care company (Medical Specialties) with a market value of $351M, the 2976th largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.19 on 6 Nov 2026.
Performance Over six months the shares gained 70.0%, against -9.6% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 7.6% over the last twelve months (peer median +7.6%); the operating margin is 26.4% (peer median 4.2%).
Valuation It trades at 3.9× forward earnings against a peer median of 21.2× (cheapest of 11).
Price implies For today's price to make sense, revenue must grow about -20% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is -20 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 25.6 points above its cost of capital (6.1% WACC).
Short interest Short interest is 10.4% of the free float (15 Oct 2026).
Next results Next results expected around 1 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.02B | $1.08B | $1.12B | $1.12B | $1.13B |
| Revenue growth | — | -4% | 0% | -1% | — |
| Gross profit | $608M | $680M | $729M | $750M | $775M |
| EBITDA | $323M | $380M | $217M | $262M | $410M |
| Net income | $87.5M | $95.4M | $78.3M | $70.4M | $224M |
| Free cash flow | $165M | $182M | $19.9M | $41.2M | $389M |
| Capital expenditure | $9.50M | $9.30M | $15.8M | $26.5M | $24.0M |
| Total debt | $1.50B | $1.45B | $1.63B | $1.66B | $1.65B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMBC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.7% | -7.5% | 4th highest of 21 |
| 6-month return | +70.0% | -9.6% | 3rd highest of 20 |
| Distance from 52-week high | -58.5% | -36.2% | 3rd lowest of 21 |
| Revenue growth (TTM) | -7.6% | +7.6% | 6th lowest of 21 |
| Operating margin | 26.4% | 4.2% | 4th highest of 21 |
| Forward P/E | 3.9× | 21.2× | cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -19.9% | 4.3% | least demanding of 12 |
| Growth delivered (Del g) | -0.1% | -0.7% | 6th highest of 12 |
| Hurdle (Req g minus delivered) | -19.8 pp | +0.8 pp | 4th least demanding of 12 |
| ROIC minus cost of capital | +25.6 pp | -4.2 pp | 3rd highest of 18 |
| EV / EBITDA | 5.1× | 11.4× | 2nd cheapest of 11 |
| Net debt / EBITDA | 4.0× | -2.6× | most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 994.0× | 22.4% | -5.1% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 11.4× | -7.6% | +16.9% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 38.5× | 20.0% | +4.4% |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 15.5× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | n/a | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 27.8× | 4.3% | +56.8% |